| Target Molecule | Linaclotide |
| Synonyms | Linzess, Constella, MD-1100, CY-14 |
| CAS Number | 851199-59-2 |
| Sequence (3-Letter) | H-Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr-OH (disulfides Cys1–Cys6, Cys2–Cys10, Cys5–Cys13) |
| Sequence (1-Letter) | CCEYCCNPACTGCY |
| Molecular Formula | C₅₉H₇₉N₁₅O₂₁S₆ |
| Molecular Weight | 1526.74 |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥98%, ≥99% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate (customizable content) or free acid options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) and Regioselective Disulfide Folding |
| Modification Options | Multi-disulfide bridging, stable isotope labeling (13C, 15N), scrambled isomer impurity standards |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | COA, HPLC, MS, and disulfide connectivity verification provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Linaclotide (CAS 851199-59-2) is a 14-amino acid peptide containing six cysteine residues that form three specific intramolecular disulfide bonds (Cys1–Cys6, Cys2–Cys10, Cys5–Cys13). We target this sequence to supply high-purity reference standards and raw materials for guanylate cyclase-C (GC-C) receptor research and analytical development.
Random oxidation of six cysteines generates complex mixtures of inactive isomers. Our peptide synthesis platform utilizes orthogonal cystine-protecting groups and sequential, directed oxidation protocols to selectively fold specific cysteine pairs, ensuring correct disulfide connectivity.
Yes. We provide specialized peptide modification services for multi-disulfide peptides. Options include the intentional synthesis of scrambled misfolded isomers as critical impurity reference standards, site-specific stable isotope labeling (13C, 15N) for quantitative LC-MS/MS, and fluorescent tagging.
Our manufacturing infrastructure scales production from milligram analytical batches to kilogram commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange to maintain consistent impurity profiles across all production volumes.
We operate as a technical partner offering complete peptide CDMO solutions. Our team manages sequence optimization, disulfide verification, impurity profiling, analytical method validation, and regulatory documentation to support complex drug development pipelines.
Linaclotide (CAS 851199-59-2) is a 14-residue peptide featuring three distinct intramolecular disulfide bonds. Synpeptide provides comprehensive synthetic solutions for this molecule, utilizing its structural complexity to demonstrate our advanced capabilities in regioselective folding and pharmaceutical peptide manufacturing.
Constructing a peptide with six cysteine residues requires exact control over chain elongation and sequential ring closure. Our custom peptide synthesis platform utilizes optimized Solid-Phase Peptide Synthesis (SPPS) protocols combined with orthogonal protecting group strategies. This systematic approach ensures high-fidelity assembly of the 14-residue backbone, consistently delivering raw materials with stringent purity profiles (typically ≥98% via HPLC) for advanced research.
The biological activity of Linaclotide depends strictly on the precise pairing of Cys1–Cys6, Cys2–Cys10, and Cys5–Cys13. Standard random oxidation methods fail to yield the correct topology. Through our peptide modification services, we execute directed oxidation cascades and verify disulfide connectivity using high-resolution LC-MS/MS, reduction-alkylation assays, and comparative peptide mapping.
Transitioning a triple-disulfide peptide from analytical scale to commercial volumes presents significant engineering challenges. We execute large-scale peptide synthesis for Linaclotide by optimizing liquid-phase handling, high-capacity preparative HPLC purification, and controlled lyophilization. This infrastructure guarantees a stable supply chain, smoothly scaling from milligram research quantities to kilogram commercial batches with exact lot-to-lot reproducibility.
We provide structural engineering and manufacturing capacity as a fully integrated peptide CDMO. Our technical teams support pharmaceutical developers through process optimization, rigorous stability assessments, and complete analytical documentation. We deliver the precise data and scalable manufacturing required to advance complex peptide APIs through the development lifecycle.
